Experimental and Molecular Medicine

Korean Society for Biochemistry and Molecular Biongy (생화학분자생물학회)
권호 표지

Anti-tumor immunostimulatory effect of heat-killed tumor cells

Yoon, Taek-Joon;Kim, Ji-Yeon;Kim, Hyo-Jeong;Hong, Chang-Wan;Lee, Hyun-Ji;Lee, Chang-Kwon;Lee, Kwang-Ho;Hong, Seok-Mann;Park, Se-Ho

  • Published : 20080000
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy:possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004;53:844-54
  2. Appleman LJ, Boussiotis VA. T cell anergy and costimulation. Immunol Rev 2003;192:161-80 https://doi.org/10.1034/j.1600-065X.2003.00009.x
  3. Avigan D. Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin Cancer Res 2004;10:6347S-52S https://doi.org/10.1158/1078-0432.CCR-050005
  4. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811 https://doi.org/10.1146/annurev.immunol.18.1.767
  5. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306 https://doi.org/10.1038/nri1592
  6. Cantor J, Haskins K. Effector function of diabetogenic CD4 Th1 T cell clones: a central role for TNF-alpha. J Immunol 2005;175:7738-45 https://doi.org/10.4049/jimmunol.175.11.7738
  7. Chang J. Efficient amplification of melanoma-specific CD8+T cells using artificial antigen presenting complex. Exp Mol Med 2006;38:591-8 https://doi.org/10.1038/emm.2006.70
  8. Chang MR, Lee WH, Choi JW, Park SO, Paik SG, Kim YS. Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2. Exp Mol Med 2005;37:240-9 https://doi.org/10.1038/emm.2005.32
  9. Cheuk AT, Chan L, Czepulkowski B, Berger SA, Yagita H, Okumura K, Farzaneh F, Mufti GJ, Guinn BA. Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunol Immunother 2006;55:68-75 https://doi.org/10.1007/s00262-005-0674-5
  10. Copier J, Dalgleish A. Overview of tumor cell-based vaccines. Int Rev Immunol 2006;25:297-319 https://doi.org/10.1080/08830180600992472
  11. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily:increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001;2:203-9 https://doi.org/10.1038/85251
  12. Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello IM, Levitsky HI, Sotomayor EM. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 2003;63:9007-15
  13. Eguchi J, Kuwashima N, Hatano M, Nishimura F, Dusak JE, Storkus WJ, Okada H. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. J Immunol 2005;174:7194-201 https://doi.org/10.4049/jimmunol.174.11.7194
  14. Emens LA. Roadmap to a better therapeutic tumor vaccine. Int Rev Immunol 2006;25:415-43 https://doi.org/10.1080/08830180600992423
  15. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003;195:346-55 https://doi.org/10.1002/jcp.10290
  16. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:383-93 https://doi.org/10.1038/nri1842
  17. Grant JF, Iwasawa T, Sinn HW, Siemens DR, Griffith TS, Takacs EB, Ratliff TL. Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNFalpha combination therapy. Int J Cancer 2006;119:2632-41 https://doi.org/10.1002/ijc.22220
  18. Gutzmer R, Li W, Sutterwala S, Lemos MP, Elizalde JI, Urtishak SL, Behrens EM, Rivers PM, Schlienger K, Laufer TM, Eck SL, Marks MS. A tumor-associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells. J Immunol 2004;173:1023-32 https://doi.org/10.4049/jimmunol.173.2.1023
  19. Hirst WJ, Buggins A, Darling D, Gaken J, Farzaneh F, Mufti GJ. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1. Gene Ther 1997;4:691-9 https://doi.org/10.1038/sj.gt.3300437
  20. Hong C, Lee H, Oh M, Kang CY, Hong S, Park SH. CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection. J Immunol 2006;177:6747-57 https://doi.org/10.4049/jimmunol.177.10.6747
  21. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95 https://doi.org/10.1038/ni1112
  22. Korbelik M, Sun J. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother 2006;55:900-9 https://doi.org/10.1007/s00262-005-0088-4
  23. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004;202:96-105 https://doi.org/10.1111/j.0105-2896.2004.00214.x
  24. Li H, Niederkorn JY, Neelam S, Mayhew E, Word RA, McCulley JP, Alizadeh H. Immunosuppressive factors secreted by human amniotic epithelial cells. Invest Ophthalmol Vis Sci 2005;46:900-7 https://doi.org/10.1167/iovs.04-0495
  25. Masse D, Voisine C, Henry F, Cordel S, Barbieux I, Josien R, Meflah K, Gregoire M, Lieubeau B. Increased vaccinationefficiency with apoptotic cells by silica-induced, dendritic-like cells. Cancer Res 2002;62:1050-6
  26. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991;145:185-92 https://doi.org/10.1016/0022-1759(91)90325-A
  27. Nouri-Shirazi M, Banchereau J, Fay J, Palucka K. Dendritic cell based tumor vaccines. Immunol Lett 2000a;74:5-10 https://doi.org/10.1016/S0165-2478(00)00243-1
  28. Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, Palucka KA. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000b;165:3797-803 https://doi.org/10.4049/jimmunol.165.7.3797
  29. Ogino T, Bandoh N, Hayashi T, Miyokawa N, Harabuchi Y, Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 2003;9:4043-51
  30. Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK. Dendritic cells as vectors for immunotherapy of cancer. Semin Cancer Biol 2003;13:439-47 https://doi.org/10.1016/j.semcancer.2003.09.008
  31. Prasad SJ, Farrand KJ, Matthews SA, Chang JH, McHugh RS, Ronchese F. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol 2005;174:90-8 https://doi.org/10.4049/jimmunol.174.1.90
  32. Rittich S, Duskova M, Mackova J, Pokorna D, Jinoch P, Smahel M. Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2. Oncol Rep 2005;13:311-7
  33. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy:moving beyond current vaccines. Nat Med 2004;10:909-15 https://doi.org/10.1038/nm1100
  34. Seliger B. Strategies of tumor immune evasion. BioDrugs 2005;19:347-54 https://doi.org/10.2165/00063030-200519060-00002
  35. Seong SY, Matzinger P. Hydrophobicity: an ancient damageassociated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004;4:469-78 https://doi.org/10.1038/nri1372
  36. Shen L, Rock KL. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol 2006;18:85-91 https://doi.org/10.1016/j.coi.2005.11.003
  37. Shi M, Su L, Hao S, Guo X, Xiang J. Fusion hybrid of dendritic cells and engineered tumor cells expressing interleukin-12 induces type 1 immune responses against tumor. Tumori 2005;91:531-8
  38. Speidel K, Osen W, Faath S, Hilgert I, Obst R, Braspenning J, Momburg F, Hammerling GJ, Rammensee HG. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens invivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol 1997;27:2391-9 https://doi.org/10.1002/eji.1830270938
  39. Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A, Vile RG. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 1999;163:1398-408
  40. Toutirais O, Chartier P, Dubois D, Bouet F, Leveque J, Catros-Quemener V, Genetet N. Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 2003;14:246-55
  41. Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S. HLA class I antigen down-regulation in primary ovary carcinoma lesions:association with disease stage. Clin Cancer Res 2005;11:67-72
  42. Wang Y, Kelly CG, Singh M, McGowan EG, Carrara AS, Bergmeier LA, Lehner T. Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70. J Immunol 2002;169:2422-9 https://doi.org/10.4049/jimmunol.169.5.2422
  43. Witham TF, Villa L, Yang T, Pollack IF, Okada H, Robbins PD, Chambers WH. Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J Neurooncol 2003;64:63-9